Year 2016 / Volume 108 / Number 1
Letter to the Editor
Graft versus host disease as a complication after liver transplantation: A rare but serious association

49-50

DOI: 10.17235/reed.2015.3722/2015

Baltasar Pérez Saborido, Enrique Asensio Díaz, Asterio Barrera Rebollo, Mario Rodríguez López, Marta Gonzalo Martín, Beatriz Madrigal Rubiales, Félix García Pajares, David Pacheco Sánchez,

Abstract
The graft versus host disease after liver transplant is rare, with an incidence less than 1%, but with a high mortality (75-85%), especially due to infectious complications. It usually affects gastrointestinal tract, skin and blood system in the context of a normal liver graft function. There is no consensus on the most appropriate treatment: some articles support a reduction or even elimination of immunosuppressive drugs, while others published success with a dose increase. Clinical case. We report a case of a 68 year-old liver transplant recipient with a graft retrieved from an ABO identical cadaveric donor. After an uneventful postoperative period, he was readmitted presenting these symptoms: skin lesions, diarrhea and kidney failure. After ruling out infectious causes or drug toxicity, skin, duodenum and colon biopsies demonstrated characteristic histological changes of graft versus host disease grade III. Initially, supportive treatment along with methylprednisolone bolus were administered with good response. However, as the doses of corticosteroids decreased, the patient worsened again, requiring basiliximab. In spite of that, the patient progressively worsened with hematological involvement and, finally, an alteration of liver function tests prior to decease. The autopsy showed CMV and Herpes virus superinfection. Discussion. We report a new case of graft-versus-host disease after liver transplantation with fatal evolution due to viral superinfection despite the employed measures.
Share Button
New comment
Comments
No comments for this article
References
1. Piton G, Larosa F, Minello A, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: a case report. Liver Transpl 2009 ;15: 682-5. doi: 10.1002/lt.21793.
2. Guo ZY, He XS, Wu LW, et al. Graft-verse-host disease after liver transplantation: A report of two cases and review of literature. World J Gastroenterol. 2008;14:974–9.
3. Taylor AL, Gibbs P, Bradley JA. Acute graft versus host disease following liver transplantation: the enemy within. Am J Transplant. 2004;4:466–74.
4. Ferrara J, Levine J, Reddy P, et al. Graft-versus-host disease. Lancet 2009;373:1550–61.
5. Gulbahce HE, Brown CA, Wick M, et al. Graft-vs-Host Disease After Solid Organ Transplant. Am J Clin Pathol. 2003;119:568–73.
6. Pollack MS, Speeg KV, Callander NS, et al. Severe, late-onset graft-versus-host disease in a liver transplant recipient documented by chimerism analysis. Hum Immunol. 2005;66:28–31.
7. Chinnakotla S, Smith DM, Domiati-Saad R, et al. Acute graft-versus-host disease after liver transplantation: role of withdrawal of immunosuppression in therapeutic management. Liver Transpl 2007;13:157-61.
8. Mawad R, Hsieh A, Damon L. Graft-versus-Host Disease Presenting With Pancytopenia After En Bloc Multiorgan Transplantation: Case Report and Literature Review. Transplant Proc 2009; 41:4431–3.
9. Thin L, Macquillan G, Adams L, et al. Acute Graft-Versus-Host Disease After Liver Transplant : Novel Use of Etanercept and the Role of Tumor Necrosis Factor alpha Inhibitors. 2009;15:421-6. Doi: 10.1002/lt.21704.
10. Xu G, Wang L, Chen W, et al. Rapamycin and tacrolimus differentially modulate acute graft-versus-host disease in rats after liver transplantation. Liver Transpl 2010;16:357–63.
11. Stotler CJ, Eghtesad B, Hsi E, et al. Rapid resolution of GVHD after orthotopic liver transplantation in a patient treated with alefacept. Blood. 2009;113:5365–6.
12. Wang B, Lu Y, Yu L, et al. Diagnosis and Treatment for Graft-Versus-Host Disease After Liver Transplantation: Two Case Reports. Transplant Proc. 2007;39:1696–8.
13. Massenkeil G, Rackwitz S, Genvresse I, et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;30:899–903.
Related articles

Digestive Diseases Image

Posterior reversible encephalopathy syndrome (PRES) in post liver transplantation

DOI: 10.17235/reed.2022.8694/2022

Letter

Ertapenem neurotoxicity in liver transplantation

DOI: 10.17235/reed.2021.8469/2021

Digestive Diseases Image

Ischemic cholangiopathy following hepatic artery pseudoaneurysm with thrombosis

DOI: 10.17235/reed.2021.8395/2021

Letter

EBVMCU in a liver-transplant patient

DOI: 10.17235/reed.2021.8064/2021

Digestive Diseases Image

Percutaneous treatment of a splenorenal shunt with an atrial septal closure device

DOI: 10.17235/reed.2020.7701/2020

Review

Physical frailty in liver transplantation

DOI: 10.17235/reed.2020.7448/2020

Letter

Management of hepatic artery aneurysms

DOI: 10.17235/reed.2020.7219/2020

Digestive Diseases Image

Epithelioid hemangioendothelioma: a rare cause of a liver tumor

DOI: 10.17235/reed.2020.7127/2020

Letter to the Editor

Post-transplant lymphoproliferative disease after liver transplantation

DOI: 10.17235/reed.2017.5387/2017

Letter to the Editor

Liver metastasis from colorectal cancer 12 years after liver transplantation

DOI: 10.17235/reed.2017.4507/2016

Citation tools
Pérez Saborido B, Asensio Díaz E, Barrera Rebollo A, Rodríguez López M, Gonzalo Martín M, Madrigal Rubiales B, et all. Graft versus host disease as a complication after liver transplantation: A rare but serious association. 3722/2015


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 914 visits.
This article has been downloaded 65 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 07/02/2015

Accepted: 17/05/2015

Online First: 05/11/2015

Published: 30/12/2015

Article revision time: 94 days

Article Online First time: 271 days

Article editing time: 326 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology